Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Zelira Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $12.21 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 9.58 million
Earnings per share -1.505
Dividend per share N/A
Year To Date Return -76.10%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Zelira Therapeutics Ltd (ASX: ZLD)
Latest News

little green pharma share price represented by cannabis leaf character jumping cheerfully
Cannabis Shares

Blazing it? How the top ASX cannabis shares performed in FY21

How did ASX cannabis shares fare in FY21?

Read more »

ASX Cannabis share price represented by asx investor holding card with cannabis leaf on it
Cannabis Shares

Why the Zelira (ASX:ZLD) share price is storming 7% higher

The Zelira Therapeutics Ltd (ASX: ZLD) share price is firmly in the green today following a positive update for its…

Read more »

A white cannabis leaf set against a green background with a graph going up, indicating a rising share price for ASX cannabis shares
Cannabis Shares

Zelira (ASX:ZLD) share price falls despite strong trading update

The Zelira Therapeutics Ltd (ASX: ZLD) share price is sliding despite announcing a positive trading update. Here's what the company…

Read more »

Share Market News

What will Elite Cannabinoids mean for ASX cannabis shares?

Private cannabis company Elite Cannabinoids has received approval for cultivation in Western Australia. What about ASX cannabis shares?

Read more »

various forms of medicinal cannabis
Cannabis Shares

CBD to be sold in pharmacies, ASX cannabis shares react

Last week, it became legal to sell cannabidiol (CBD) products in chemists and pharmacies. We take a look at the…

Read more »

cannabis leaves on a rising line graph representing growth of ASX cannabis share price
Share Market News

The sector that’ll grow 480% this year, expert says

Can you smell that? That's the fragrance of a booming industry, which is still in a startup phase in Australia.

Read more »

medical marijuana, cannabis, pot, drug, medical
Best Shares

5 top ASX cannabis shares in 2020

We take a closer look at the 5 top ASX cannabis shares in 2020 and how they delivered for shareholders…

Read more »

man walking up line graph, into clouds, representing asx shares at an all time high
Share Market News

Here’s why the Zelira (ASX:ZLD) share price just rocketed to a new high

The Zelira Therapeutics Ltd (ASX: ZLD) share price is rocketing higher today after announcing a new licencing agreement with Alternative…

Read more »

ZLD ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Zelira Therapeutics Ltd

Zelira Therapeutics Ltd (ASX: ZLD) is a leading global therapeutic medicinal cannabis company with access to the world’s fastest growing cannabis markets. Formerly Zelda Therapeutics, Zelira owns a portfolio of proprietary products and a pipeline of candidates undergoing clinical development.

The company focus is on developing branded cannabis products for the treatment of a variety of medical conditions, including insomnia, autism and opioid reduction. Zelira has launched two proprietary formulations under the HOPE brand for autism in multiple US-states with plans to expand into global markets in 2020. 

ZLD Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 May 2022 $1.38 $0.21 17.87% 21,309 $1.18 $1.40 $1.18
16 May 2022 $1.18 $-0.09 -7.14% 10,800 $1.26 $1.30 $1.18
13 May 2022 $1.26 $-0.02 -1.56% 9,589 $1.28 $1.29 $1.26
12 May 2022 $1.28 $0.00 0.00% 7,674 $1.29 $1.29 $1.27
11 May 2022 $1.28 $-0.01 -0.78% 15,063 $1.29 $1.29 $1.25
10 May 2022 $1.29 $-0.01 -0.77% 7,409 $1.30 $1.35 $1.28
09 May 2022 $1.30 $0.02 1.56% 6,268 $1.28 $1.30 $1.28
06 May 2022 $1.28 $-0.12 -8.60% 10,782 $1.36 $1.40 $1.25
05 May 2022 $1.40 $-0.05 -3.45% 17,645 $1.35 $1.40 $1.25
04 May 2022 $1.45 $-0.07 -4.61% 17,947 $1.50 $1.50 $1.45
03 May 2022 $1.52 $-0.20 -11.63% 28,909 $1.72 $1.72 $1.50
02 May 2022 $1.72 $-0.28 -14.00% 7,965 $1.97 $1.97 $1.70
29 Apr 2022 $2.00 $-0.11 -5.21% 14,026 $2.10 $2.10 $1.96

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Feb 2022 Osagie Imasogie Buy 58 $1,641,954
Conversion of securities.
03 Feb 2022 Osagie Imasogie Exercise 58 $1,641,954
Conversion of securities. 58,641,228 performance rights
03 Feb 2022 Harry Karelis Buy 6 $175,000
Conversion of securities.
03 Feb 2022 Lisa Gray Exercise 58 $1,641,954
Conversion of securities. 58,641,228 performance rights
03 Feb 2022 Harry Karelis Exercise 6 $175,000
Conversion of securities. 6,250,000 performance rights
03 Feb 2022 Lisa Gray Buy 58 $1,641,954
Conversion of securities.
03 Feb 2022 Oludare Odumosu Buy 17 $491,633
Conversion of securities.
03 Feb 2022 Oludare Odumosu Exercise 17 $491,633
Conversion of securities. 17,558,328 performance rights
17 Nov 2021 Jason Peterson Expiry 8 $304,000
Options expired.
17 Nov 2021 Harry Karelis Expiry 6 $228,000
Options expired.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Timothy (Tim) Ryan Slate Company SecretaryNon-Executive Director Dec 2016
Mr Slate has over 15 years' of experience and provides accounting, secretarial and corporate advice to a number of private and public companies.
Dr Oludare Odumosu Managing Director Dec 2019
Dr Odumosu spent 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a combination of experiences from several academic, public health and life science organisations. In his recent role as Ilera Healthcare's first Chief Operating Officer, Dr Odumosu led the design, implementation and management of Ilera's business operation's post license award in 2017 through successful, market entry, product commercialization to profitability in 2018. He was also responsible for oversight and management of day to day operation of Ilera's vertically integrated grow/processor, wholesale and dispensary. In the same capacity, He led the formulation of Ilera proprietary cannabinoid-based product. His transition to Chief Scientific Officer/EVP Pharmaceutical Division resulted in a series of product development partnerships and the successful creation of Ilera Therapeutics. Dr Odumosu is World Bank Institute Certified public health professional.
Mr Osagie Imasogie Non-Executive ChairmanNon-Executive Director Dec 2019
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualised and established GlaxoSmithKline Ventures and was its founding Vice President. Mr. Imasogie has held senior legal, commercial and R&D positions within pharmaceutical companies such as GSK, SmithKline, DuPont Merck and Endo, where he was the founding General Counsel and SVP for Corporate Development. Osagie has also been a Price Waterhouse Corporate Finance Partner as well as a practicing attorney with a leading US Law Firm. He is also Trustee of the University of Pennsylvania, a member of the Executive Committee and former Chairman of the Budget & Finance Committee of the University. He is Chairman of the Board of the University of Pennsylvania Law School - Adjunct Professor of Law.
Ms Lisa Gray Non-Executive Director Dec 2019
Ms Gray has experience in finance, marketing, business development, and operations primarily within the pharmaceutical industry. Lisa was Co-Founder and Vice Chair of Ilera Healthcare, a vertically integrated Grower, Processor and Dispenser of Medicinal Marijuana in Pennsylvania, and was a lead on the sale of this business. Lisa is also the Co-Founder and Managing Partner of PIPV Capital, a Private Equity firm focused on building companies in life sciences, where she manages the financial aspects of the firm and portfolio, generates and leads investments, manages investor communications, and acts as Board Member CEO, CFO, and/or plays various management roles, as necessary, for portfolio companies. Lisa has previously served as COO for GlaxoSmithKline (GSK) Pharmaceuticals Ventures, a pharmaceutical venture fund, as well as other operations and transactions roles over 13 years with GSK. Prior to joining GSK, Lisa was a management consultant and auditor with Coopers & Lybrand.

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
No Top 20 Shareholder Information 0 0.00%